Midwest Biomedical Accelerator Consortium: MBArC

项目概要/摘要 生物医学研究的最终目标是创造新的设备，药物和技术， 预防、诊断和治疗人类疾病。比如科学发现，生物医学技术 商业化是复杂的，需要指导、资源、协作和风险。 然而，一些障碍限制了有前途的实验室发现的商业化，包括 1)学术界缺乏对商业化是一种选择的认识，2）担心 商业化努力延迟学术进步，3）未能连接研究人员 与合作者和专家一起完成商业化过程。的 该研究评估和商业化中心（REACH）提案的目标是 建立密苏里-哥伦比亚大学（MU）和密苏里大学之间的伙伴关系， 堪萨斯医疗中心（KUMC）将促进学术创业， 商业化在这次合作中，MU带来了其杰出的生物医学和生物工程 研究计划及其参与库尔特翻译的充满活力的记录 研究合作伙伴奖计划。KUMC提供其卓越的生物医学研究 项目和前沿，其NIH临床和转化科学奖（CTSA）。此外，本发明还提供了一种方法， 每个机构都有现有的伙伴关系，加强和扩大联盟-即1）MU与 密苏里州州立系统大学，位于堪萨斯城、圣路易斯和罗拉; 2）KUMC 与堪萨斯生物医学研究卓越理念网络（K-INBRE）和可持续发展 Heartland Accelerator Regional Partnership Hub（SHARPhub）该组织的领导团队 一个名为中西部生物医学加速器联盟（MBArC）的网络将采用 以下战略，以提高生物医学研究的商业化：1）利用MBArC的 发展战略伙伴关系，邀请科学家 从事技术转让和商业化，2）培养院士， 验证其创新的临床和商业可行性所需的资源，3）提供 研究人员与资金和指导，以完成产品定义研究，并吸引以下- 4）提供生物医学创新方面的体验式学习机会， 创业这项倡议将建立在优秀机构的现有方案的基础上， 在密苏里州、堪萨斯 和相邻的国家。MBArC REACH Hub将促进新科学技术的商业化 建立可持续的基础设施，将科学发现转化为 预防和治疗困扰美国人口的高负担疾病的商业产品。

Project Summary/Abstract The ultimate goal of biomedical research is to create new devices, drugs, and technologies that prevent, diagnose, and treat human diseases. Like scientific discovery, biomedical technology commercialization is complex and requires mentorship, resources, collaboration, and risk. However, several hurdles limit commercialization of promising laboratory discoveries, including 1) lack of awareness by academicians that commercialization is an option, 2) concerns that commercialization efforts delay academic advancement, and 3) failure to connect investigators with the collaborators and experts necessary to complete the commercialization process. The objective of this Research Evaluation and Commercialization Hub (REACH) proposal is to establish a partnership between the University of Missouri-Columbia (MU) and the University of Kansas Medical Center (KUMC) that will promote academic entrepreneurship and commercialization. To this collaboration MU brings its outstanding biomedical and bioengineering research programs and its vibrant track record of participation in the Coulter Translational Research Partnership Award program. KUMC provides its exceptional biomedical research programs and Frontiers, its NIH Clinical and Translational Science Award (CTSA). In addition, each institution has existing partnerships that strengthen and extend the alliance - i.e. 1) MU with University of Missouri state system universities in Kansas City, St. Louis, and Rolla; and 2) KUMC with the Kansas Idea Network of Biomedical Research Excellence (K-INBRE) and the Sustainable Heartland Accelerator Regional Partnership Hub (SHARPhub). The leadership team of this network, entitled the Midwest Biomedical Accelerator Consortium (MBArC), will employ the following strategies to increase biomedical research commercialization: 1) leverage MBArC’s geographic and institutional scope to develop strategic partnerships that invite scientists to engage in technology transfer and commercialization, 2) give academicians the training and resources needed to validate the clinical and commercial feasibility of their innovations, 3) provide researchers with funding and mentorship to complete product definition studies and attract follow- on funding, and 4) offer experiential learning opportunities in biomedical innovation and entrepreneurship. This initiative will build on existing programs in outstanding institutions to increase health-related business development, including small businesses, in Missouri, Kansas, and adjoining states. The MBArC REACH Hub will promote commercialization of novel scientific discoveries and establish a sustainable infrastructure to translate scientific discoveries into commercial products that prevent and treat high-burden diseases afflicting the US population.